Completed PHASE3 INTERVENTIONAL NCT00029835

Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias

Sponsor: Sanofi

Conditions Dyslipidemia Obesity

Interventions Rimonabant (SR141716)

Updated 7 times since 2017 Last updated: Apr 17, 2009 Started: Sep 30, 2001 Primary completion: Nov 30, 2003 Completion: Nov 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Dyslipidemia and Obesity and is currently completed. Sanofi leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Arden Hills, United States , Barcelona, Spain , Bismarck, United States , Bromma, Sweden , Charleston, United States , Cincinnati, United States , Coral Gables, United States , Duncansville, United States , Edina, United States and 25 more locations